| HOME >> MEDICINE >> TECHNOLOGY |
Overview of Select Protease Inhibitors II-7
Kaletra (lopinavir/ritonavir) II-7
Reyataz (Atazanavir) II-7
Prezista (Darunavir) II-8
Viracept (nelfinavir mesylate) II-8
Kaletra and Reyataz to Maintain Market Dominance II-8
Nucleoside Reverse Transcriptase Inhibitors II-9
Approved NRTI Drugs; Dosing and Frequency II-9
Overview of Select NRTIs II-9
Emtriva (emtricitabine) II-9
Stavudine (Zerit)- Marred with Safety Issues II-9
Safety Concerns to Curb Ziagen's Use II-10
Non-Nucleoside Reverse Transcriptase Inhibitors II-10
Overview of Select NNRTIs II-10
Viramune® (nevirapine) II-10
Intelence (Etravirine) II-10
Integrase Inhibitors II-11
Overview of Select Integrase Inhibitors II-11
Isentress (Raltegravir) II-11
Elvitegravir (Gilead Sciences) II-11
Chemokine Receptor 5 Inhibitors II-11
Selzentry (maraviroc) II-12
Selzentry Makes a Slow Start II-12
Fusion Inhibitors II-12
Combination Therapy II-13
Drug Resistance Issues Fuel Use of Combination Therapy II-13
Atripla (Bristol-Myers Squibb and Gilead Sciences) II-14
Epzicom (GlaxoSmithKline) II-14
Qua
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |